In Follow Up
Surmount-4
In Follow Up, Obesity
This is a study of tirzepatide in participants with obesity or overweight. The main purpose is to learn more about how tirzepatide maintains…
Alpaca
In Follow Up, Lipoprotein (a)
The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will…
Influenza Vaccine
In Follow Up
This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of…
Azalea A Fib
In Follow Up
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial…
Bavarian RSV
In Follow Up
Phase 3 randomized, double- blind study comparing recombinant MVA-BN-RSV vaccine vs placebo for efficacy and safety in adults >=60 years of…
Renoir
In Follow Up
This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of RSVpreF…
Arrowhead
In Follow Up, High Triglyceride
The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will…
V-Initiate
Cholesterol, In Follow Up
The purpose of this study is to assess the effectiveness of an "inclisiran first" implementation strategy (addition of inclisiran to…
Empact
In Follow Up, Heart Attack
This is a study in adults who had a heart attack (myocardial infarction). The purpose of this study is to find out whether a medicine called…
Transcend
In Follow Up
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials…
Vesalius-cv
In Follow Up, Cholesterol
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in…
SURPASS-CVOT
In Follow Up
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and…